Stocks Industrials CTKB
NASDAQ · IndustrialsCytek Biosciences, Inc. (CTKB)
Cytek Biosciences, Inc. brought in $206.7M of revenue over the twelve months to June 30, 2026, up 5.4% from a year earlier. It posted a net loss of $80.6M. In fiscal 2025 capital spending exceeded operating cash flow by $8.8M. At June 30, 2026 it held $73.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.
What Cytek Biosciences, Inc. does
Cytek Biosciences, Inc. is registered with the SEC under industry code SIC 3826 (Laboratory Analytical Instruments). Its shares trade on NASDAQ under the ticker CTKB.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $201.5M | -$66.5M | n/a | -$8.8M |
| 2024 | $200.5M | -$6M | n/a | $21.9M |
| 2023 | $193M | -$12.1M | -$0.09 | $633K |
| 2022 | $164M | $2.5M | $0.02 | -$22M |
| 2021 | $128M | $3M | $0.00 | $266K |
| 2021 | $92.8M | $19.4M | $0.10 | $13.6M |
Latest SEC filings
What Cytek Biosciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 24, 2026
- August 6, 2026Passive stake changed SCHEDULE 13G/A
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026
- August 5, 2026
- August 4, 2026Passive stake (5% or more) SCHEDULE 13G
- July 15, 2026
- July 8, 2026Passive stake changed SCHEDULE 13G/A
- June 25, 2026
- June 16, 2026
- June 2, 2026
Questions about CTKB
What does Cytek Biosciences, Inc. do?
Cytek Biosciences, Inc. is registered with the SEC under industry code SIC 3826 (Laboratory Analytical Instruments). Its shares trade on NASDAQ under the ticker CTKB.
Is Cytek Biosciences, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $80.6M on revenue of $206.7M.
How much revenue does Cytek Biosciences, Inc. make?
Over the twelve months to June 30, 2026 Cytek Biosciences, Inc. reported revenue of $206.7M. That is 5.4% more than a year earlier.
When did Cytek Biosciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the planned insider sale from September 2, 2026.
Similar companies
Follow CTKB
Get an email when Cytek Biosciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow CTKB: get an email when it filesWhere the numbers come from
Financial figures are the values Cytek Biosciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.